Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association between p53 Gene Variants and Oral Cancer Susceptibility in Population from Gujarat, West India

  • Patel, Kinjal R. (Biochemistry Research Division) ;
  • Vajaria, Bhairavi N. (Biochemistry Research Division) ;
  • Begum, Rasheedunnisa (Department of Biochemistry, The M. S. University of Baroda) ;
  • Shah, Franky D. (Biochemistry Research Division) ;
  • Patel, Jayendra B. (Biochemistry Research Division) ;
  • Shukla, Shilin N. (The Gujarat Cancer and Research Institute) ;
  • Patel, Prabhudas S. (Biochemistry Research Division)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: p53 gene variants i.e. 16 bp duplication in intron 3, Arg72Pro in exon 4 and G>A in intron 6 have been reported to modulate susceptibility to various malignancies. Therefore, the present study evaluated the role of these p53 polymorphisms in oral cancer susceptibility in a population from Gujarat, West India. Method: Genotype frequencies at the three p53 loci in 110 controls and 79 oral cancer cases were determined by the PCR-RFLP method. Results: Heterozygous individuals at exon 4 showed protection from developing oral cancer. Homozygous wild and heterozygous individuals at intron 3 and those heterozygous at exon 4 in combination appeared to be at lowered risk. Furthermore, carriers of the 16 bp duplication allele at intron 3, proline allele at exon 4 and G allele at intron 6 were protected from oral cancer development. Conclusion: p53 polymorphisms, especially Arg72Pro in exon 4 could significantly modify the risk of oral cancer development in Gujarat, West Indian population.

Keywords

References

  1. Avigad S, Barel D, Blau O, et al (1997). A novel germ line p53mutation in intron 6 in diverse childhood malignancies. Oncogene, 14, 1541-5. https://doi.org/10.1038/sj.onc.1200990
  2. Azzam GA, Frank AK, Hollstein M, Murphy ME (2011). Tissue-specific apoptotic effects of the p53 codon 72 polymophism in a mouse model. Cell Cycle, 10, 1352-5. https://doi.org/10.4161/cc.10.9.15344
  3. Beckman G, Birgander R, Sjalander A, et al (1994). Is p53polymorphism maintained by natural selection? Hum Hered, 44, 266-70. https://doi.org/10.1159/000154228
  4. Beenken SW, Karsenty G, Raycroft L, Lozano G (1991). An intron binding protein is required for transformation ability of p53. Nucleic Acids Res, 19, 4747-52. https://doi.org/10.1093/nar/19.17.4747
  5. Bergamaschi D, Gasco M, Hiller L, et al (2003). p53polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402. https://doi.org/10.1016/S1535-6108(03)00079-5
  6. Chakrabarti S, Dasgupta S, Roy S, et al (2001). Microsatellite instability in squamous cell carcinoma of head and neck from the Indian patient population. Int J Cancer, 92, 555-61. https://doi.org/10.1002/ijc.1233
  7. Chumakov PM, Jenkins JR (1991). BstNI/NciI polymorphism of the human p53 gene (TP53). Nucleic Acids Res, 19, 6969.
  8. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65. https://doi.org/10.1038/ng1093
  9. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC (1993). Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet, 53, 752-9.
  10. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  11. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011). Arg72Pro P53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer, 129, 920-30. https://doi.org/10.1002/ijc.25710
  12. Frank AK, Leu JI, Zhou Y, et al (2011). The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol, 31, 1201-13. https://doi.org/10.1128/MCB.01136-10
  13. Galli P, Cadoni G, Volante M, et al (2009). A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer, 9, 137. https://doi.org/10.1186/1471-2407-9-137
  14. Gemignani F, Moreno V, Landi S, et al (2004). A TP53polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23, 1954-6. https://doi.org/10.1038/sj.onc.1207305
  15. Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B (2009). Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep, 22, 1205-11.
  16. Hsieh LL, Huang TH, Chen IH, et al (2005). p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer, 92, 30-5. https://doi.org/10.1038/sj.bjc.6602271
  17. Hu Z, Li C, Chen K, et al (2008). Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol, 2008, 147905.
  18. Hu Z, Li X, Qu X, et al (2010). Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis, 31, 643-7. https://doi.org/10.1093/carcin/bgq018
  19. Imyanitov EN, Togo AV, Hanson KP (2004). Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett, 204, 3-14. https://doi.org/10.1016/j.canlet.2003.09.026
  20. Katiyar S, Thelma BK, Murthy NS, et al (2003). Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem, 252, 117-24. https://doi.org/10.1023/A:1025546610920
  21. Khaliq S, Hameed A, Khaliq T, et al (2000). P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test, 4, 23-9. https://doi.org/10.1089/109065700316435
  22. Kietthubthew S, Sriplung H, Au WW, Ishida T (2003). The p53Codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev, 4, 209-14.
  23. Kuroda Y, Nakao H, Ikemura K, Katoh T (2007). Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol, 43, 1043-8. https://doi.org/10.1016/j.oraloncology.2006.12.001
  24. Lazar V, Hazard F, Bertin F, et al (1993). Simple sequence repeat polymorphism within the p53 gene. Oncogene, 8, 1703-5.
  25. Lehman TA, Haffty BG, Carbone CJ, et al (2000). Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res, 60, 1062-9.
  26. Lozano G, Levine AJ (1991). Tissue-specific expression of p53in transgenic mice is regulated by intron sequences. Mol Carcinog, 4, 3-9. https://doi.org/10.1002/mc.2940040103
  27. Matlashewski GJ, Tuck S, Pim D, et al (1987). Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol, 7, 961-3.
  28. Mattick JS (1994). Introns: evolution and function. Curr Opin Genet Dev, 4, 823-31. https://doi.org/10.1016/0959-437X(94)90066-3
  29. Mitra S, Chatterjee S, Panda CK, et al (2003). Haplotype structure of TP53 locus in Indian population and possible association with head and neck cancer. Ann Hum Genet, 67, 26-34. https://doi.org/10.1046/j.1469-1809.2003.00005.x
  30. Mitra S, Sikdar N, Misra C, et al (2005). Risk assessment of p53genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int J Cancer, 117, 786-93. https://doi.org/10.1002/ijc.21263
  31. Mittal RD, George GP, Mishra J, Mittal T, Kapoor R (2011). Role of functional polymorphisms of p53 and p73 genes with the risk of prostate cancer in a case-control study from Northern India. Arch Med Res, 42, 122-7. https://doi.org/10.1016/j.arcmed.2011.03.001
  32. Nagpal JK, Patnaik S, Das BR (2002). Prevalence of high-risk human papilloma virus types and its association with p53codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer, 97, 649-53. https://doi.org/10.1002/ijc.10112
  33. Ozeki C, Sawai Y, Shibata T, et al (2011). Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem, 286, 18251-60. https://doi.org/10.1074/jbc.M110.208587
  34. Pandith AA, Shah ZA, Khan NP, et al (2010). Role of TP53Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet, 203, 263-8. https://doi.org/10.1016/j.cancergencyto.2010.08.010
  35. Paterson IC, Eveson JW, Prime SS (1996). Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol, 32, 150-3. https://doi.org/10.1016/0964-1955(95)00065-8
  36. Pim D, Banks L (2004). p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer, 108, 196-9. https://doi.org/10.1002/ijc.11548
  37. Saini R, Tang TH, Zain RB, et al (2011). Significant association of high-risk human papillomavirus (HPV) but not of p53polymorphisms with oral squamous cell carcinomas in Malaysia. J Cancer Res Clin Oncol, 137, 311-20. https://doi.org/10.1007/s00432-010-0886-8
  38. Sameer S, Shah ZA, Syeed N, et al (2010). TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predispostion in an ethinic Kashmiri population. Genet Mol Res, 9, 651-60. https://doi.org/10.4238/vol9-2gmr751
  39. Schneider-Stock R, Mawrin C, Motsch C, et al (2004). Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol, 164, 1233-41. https://doi.org/10.1016/S0002-9440(10)63211-7
  40. Shamsher M, Montano X (1996). Analysis of intron 4 of the p53gene in human cutaneous melanoma. Gene, 176, 259-62. https://doi.org/10.1016/0378-1119(96)00000-5
  41. Sprague BL, Trentham-Dietz A, Garcia-Closas M, et al (2007). Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis, 28, 1680-6. https://doi.org/10.1093/carcin/bgm097
  42. Stephens M, Smith NJ, Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet, 68, 978-89. https://doi.org/10.1086/319501
  43. Storey A, Thomas M, Kalita A, et al (1998). Role of a p53polymorphism in the development of human papillomavirus-associated cancer. Nature, 393, 229-34. https://doi.org/10.1038/30400
  44. Suresh K, Chandiraasekar R, Kumar BL, Venkatesan R, Sasikala K (2010). No association between the TP53 codon 72 polymorphism and Head and Neck Cancer: A case-control study in a south Indian population. Asian Pac J Cancer Prev, 11, 1749-53.
  45. Suresh K, Venkatesan R, Chandirasekar R, Kumar BL, Sasikala K (2011). Association of TP53 Arg72Pro polymorphic variants with breast cancer - a case control study in south Indian population. Biology and Medicine, 3, 15-22.
  46. Tandle AT, Sanghvi V, Saranath D (2001). Determination of p53genotypes in oral cancer patients from India. Br J Cancer, 84, 739-42. https://doi.org/10.1054/bjoc.2000.1674
  47. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
  48. Wang-Gohrke S, Weikel W, Risch H, et al (1999). Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer, 81, 179-83. https://doi.org/10.1038/sj.bjc.6690669
  49. Weston A, Wolff MS, Morabia A, et al (1998). True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet, 102, 153-4. https://doi.org/10.1016/S0165-4608(97)00349-X
  50. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
  51. Wu X, Zhao H, Amos CI, et al (2002). p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst, 94, 681-90. https://doi.org/10.1093/jnci/94.9.681
  52. Zhu F, Dolle ME, Berton TR, et al (2010). Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res, 70, 5851-9. https://doi.org/10.1158/0008-5472.CAN-09-4646
  53. Zhuo XL, Li Q, Zhou Y, et al (2009). Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res, 40, 625-34. https://doi.org/10.1016/j.arcmed.2009.09.004

Cited by

  1. Association of a p53 Codon 72 Gene Polymorphism with Environmental Factors and Risk of Lung Cancer: a Case Control Study in Mizoram and Manipur, a High Incidence Region in North East India vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10653
  2. P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility vol.16, pp.1, 2015, https://doi.org/10.1186/s12863-015-0235-7
  3. Association of P53 (−16ins-Pro) Haplotype with the Decreased Risk of Differentiated Thyroid Carcinoma in Iranian-Azeri Patients vol.21, pp.2, 2015, https://doi.org/10.1007/s12253-014-9846-y
  4. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1243
  5. Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317699113
  6. Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis vol.18, pp.1, 2018, https://doi.org/10.1186/s12903-018-0603-6
  7. Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer vol.9, pp.1664-042X, 2018, https://doi.org/10.3389/fphys.2018.01014
  8. Salivary protease spectrum biomarkers of oral cancer vol.11, pp.1, 2019, https://doi.org/10.1038/s41368-018-0032-z